Explore our newest products
We are a world leader in pharmaceutical excipients, vaccine adjuvants and lipid delivery systems for human and veterinary applications.
Find out more information on our newest products:
Super Refined™ Poloxamer 188
Super Refined™ Poloxamer 188 is added to cell culture media to protect cells from shear stress caused by agitation in a bioreactor. Super Refined™ Poloxamer 188 has been optimised specifically for mammalian cell culture with tightly controlled impurity profiles and molecular weight, ensuring optimal cell culture performance and batch-to-batch consistency.
Sustainable Squalene
Introducing our Sustainable Squalene, produced using cutting-edge technology that centres on synthetic biology, our pharmaceutical-grade squalene has superior purity and carries the same squalene benefits as shark-derived squalene.
Sustainable saponins (2024)
As we look to become more nature positive, we’re proud to be able to offer our next-generation QS 21 and support global sustainability efforts. Our next-generation QS 21 is based on plant tissue culture, which makes the process more efficient and sustainably sourced.
Introducing Virodex™
We’re introducing our new range of detergents specifically designed to support the key steps in your biomanufacturing processes.
Introducing NatraPhos™, our highly purified, natural phospholipids:
4 items available
NatraPhos Soya PC100-C Pharma
NatraPhos™ Soya PC100-C is a highly purified soybean lecithin containing predominantly phosphatidylcholine.
NatraPhos™ PL95E Pharma
NatraPhos™ PL95E is a highly purified egg yolk lecithin containing predominantly phosphatidylcholine and a smaller amount of phosphatidylethanolamine.
NatraPhos™ Soya PC80-C Pharma
NatraPhos™ Soya PC80-C is a highly purified soybean lecithin containing predominantly phosphatidylcholine.
NatraPhos™ PL95EN Pharma
NatraPhos™ PL95EN is a highly purified egg yolk lecithin containing predominantly phosphatidylcholine and a smaller amount of phosphatidylethanolamine.
How we empower biologics delivery
Explore recent blogs:
Croda welcomes Thomas Riermeier as new President of Life Sciences
Croda International Plc, the company that uses smart science to create ingredients and technologies that improve lives, today announces that Dr. Thomas Riermeier has been appointed as the new...
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=4F9521E2A9CDAB872D1AA12B9BA9F4EB)
From Lab to Patient: Optimising Oncology Formulations with Purified Excipients
In 2024, we hosted a live webinar exploring the impact of our Super RefinedTM excipients on various chemotherapeutic formulations. This blog will explore some of the key learnings from the webinar.
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=F330DFD631D5F6E81578038D37E005ED){kind=logo}
Croda’s Avanti Research expands ionizable lipid offering for LNP drug development through Certest collaboration
Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, and Certest Biotec S.L. (Certest) are pleased to announce a strategic collaboration to expand the market’s access to...